Evidence map›Paper›PMID 29029884›Full record

ArticleInternational journal of radiation oncology, biology, physics2018

Identification of ATIC as a Novel Target for Chemoradiosensitization.

Xiangfei Liu, Uma Devi Paila, Sharon N Teraoka, Jocyndra A Wright, Xin Huang, Aaron R Quinlan, Richard A Gatti, Patrick Concannon

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xiangfei LiuGenetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Uma Devi PailaDepartment of Public Health Sciences, Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Sharon N TeraokaGenetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Jocyndra A WrightGenetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Xin HuangGenetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Aaron R QuinlanDepartment of Human Genetics, University of Utah, Salt Lake City, Utah; Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah.
Richard A GattiDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California; Department of Human Genetics, University of California, Los Angeles, Los Angeles, California.
Patrick ConcannonGenetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida. Electronic address: patcon@ufl.edu.
University of Florida · USOffice of Public Health Genomics · USUniversity of California, Los Angeles · USUniversity of Utah · US

Funding

Novel DNA damage response gene from genomic screeningR01ES027121 · NIEHS · UNIVERSITY OF FLORIDA · PI CONCANNON, PATRICK · 2016 to 2020
$1.6M
Identification of radiation sensitivity alleles by whole exome sequencingR21ES020521 · NIEHS · UNIVERSITY OF VIRGINIA · PI CONCANNON, PATRICK · 2011 to 2012
$432k
NIEHS NIH HHS R01 ES027121NIEHS NIH HHS R21 ES020521
6 · The paper itself

Abstract

purposeMutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functional studies were performed to determine whether ATIC inhibition was radiosensitizing and, if so, to elucidate the mechanism of this effect and determine whether small molecule inhibitors of ATIC could act as effective radiosensitizing agents. METHODS AND MATERIALS: Both small interfering RNA knockdown and small molecule inhibitors were used to inactivate ATIC in cell culture. Clonogenic survival assays, the neutral comet assay, and γH2AX staining were used to assess the effects of ATIC inhibition or depletion on cellular DNA damage responses.

resultsDepletion of ATIC or inhibition of its transformylase activity significantly reduced the surviving fraction of cells in clonogenic survival assays in multiple cancer cell lines. In the absence of ionizing radiation exposure, ATIC knockdown or chemical inhibition activated cell cycle checkpoints, shifting cells to the more radiosensitive G2/M phase of the cell cycle, and depleted cellular adenosine triphosphate but did not result in detectable DNA damage. Cells in which ATIC was knocked down or inhibited and then treated with ionizing radiation displayed increased numbers of DNA double-strand breaks and a delay in the repair of those breaks relative to irradiated, but otherwise untreated, controls. Supplementation of culture media with exogenous adenosine triphosphate ameliorated the DNA repair phenotypes.

conclusionsThese findings implicate ATIC as an effective, and previously unrecognized, target for chemoradiosensitization and, more broadly, suggest that purine levels in cells might have an underappreciated role in modulating the efficiency of DNA damage responses that could be exploited in radiosensitizing strategies.

Indexed as

ChemoradiotherapyDNA Breaks, Double-StrandedFrameshift MutationAdenosine TriphosphateCell Cycle CheckpointsCell Line, TumorCell SurvivalComet AssayDNA DamageDNA RepairEnzyme InhibitorsGene Knockdown TechniquesHistonesHumansHydroxymethyl and Formyl TransferasesMolecular Targeted TherapyAdenosine TriphosphateEnzyme InhibitorsH2AX protein, humanHistonesHydroxymethyl and Formyl Transferasesinosine monophosphate synthaseMultienzyme ComplexesNeoplasm ProteinsNucleotide DeaminasesRadiation-Sensitizing Agents

Identifiers

PMID29029884
PMCPMC5736427
OpenAlexW2759964552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.